Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
10028 Results for "
Modification
" in MedChemExpress (MCE) Product Catalog:
Products (10028)
10028 Results for "Modification" in MCE Product Catalog:
147
147 Publications Verification
Synonyms: Diferuloylmethane; Natural Yellow 3; Turmeric yellow
35
Category:
Infection Acanthaceae Extract Plant Terpenoids Diterpenoids Disease Research Fields Inflammation/Immunology Andrographis paniculata (Burm. F.) Nees Extract
Target:
27
27 Cited Publications
Target:
Forschungsgebiete:
mPEG2000-DMG is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. mPEG2000-DMG is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .
26
Target:
Leptomycin B (CI 940; LMB) is a potent inhibitor of the nuclear export of proteins. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue. Leptomycin B is a potent antifungal antibiotic blocking the eukaryotic cell cycle .
8
8 Cited Publications
Synonyms: 6-Methyladenosine; N-Methyladenosine
Target:
6
6 Cited Publications
Target:
Forschungsgebiete:
GAL-021 is a potent BKCa-channel blocker. GAL-021 inhibits KCa1.1 in GH3 cells. GAL-021 is a novel breathing control modulator that is based on selective modification of the almitrine pharmacophore. GAL-021 increases minute ventilation in rats and non-human primates .
6
6 Cited Publications
Target:
Forschungsgebiete:
EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
5
5 Cited Publications
Category:
Alkaloids Other Diseases Disease markers Endogenous metabolite Disease Research Fields Cervical Cancer Markers Cancer
Target:
4
Category:
Natural Products Other disease Disease markers Endogenous metabolite Disease Research Fields Cancer
Target:
4
4 Cited Publications
Art. -Nr.: HY-B0162
CAS. Nr.: 155974-00-8
Target:
Forschungsgebiete:
Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity .
4
4 Cited Publications
Art. -Nr.: HY-B0162A
CAS. Nr.: 148849-67-6
Target:
Forschungsgebiete:
Cardiovascular Disease Infection Neurological Disease Metabolic Disease Cancer
Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity .
4
4 Cited Publications
Target:
Forschungsgebiete:
IDH1 Inhibitor 2 (compound 13) is a potent wild-type IDH1 inhibitor that exerts its activity through covalent modification of His315 with an IC50 value of 110 nM. IDH1 Inhibitor 2 can dose-dependently reduce the intracellular reduced glutamine metabolic flux, thereby affecting cellular metabolic homeostasis. IDH1 Inhibitor 2 can be used to study the role of IDH1 in cellular metabolic regulation and cancer development .
3
Category:
Natural Products Other Diseases Microorganism Endogenous metabolite Disease Research Fields
Target:
3
3 Cited Publications
Forschungsgebiete:
Gln-AMS is a potent inhibitor of Aminoacyl-tRNA Synthetase. Gln-AMS blocks the lactylation modification of downstream targets through competitive binding to AARS1, thereby regulating apoptosis, ferroptosis, and the transcriptional processes of related genes. Gln-AMS can be used in research on breast cancer, diabetic nephropathy, and sepsis-associated encephalopathy .
3
3 Cited Publications
Art. -Nr.: HY-W441014
DSPE-PEG2000-NHS is a PEG-modified phospholipid derivative that can be used to prepare liposomes. DSPE-PEG2000-NHS is commonly employed as a linker molecule for the surface modification of liposomes to confer targeting capabilities. DSPE-PEG2000-NHS can be used in the study of drug delivery .
3
3 Cited Publications
Art. -Nr.: HY-112861A
Reinheit: 99.65%
Gln-AMS TFA is a potent inhibitor of Aminoacyl-tRNA Synthetase. Gln-AMS TFA blocks the lactylation modification of downstream targets through competitive binding to AARS1, thereby regulating apoptosis, ferroptosis, and the transcriptional processes of related genes. Gln-AMS TFA can be used in research on breast cancer, diabetic nephropathy, and sepsis-associated encephalopathy .
3
3 Cited Publications
Art. -Nr.: HY-RI04602A
MicroRNA Antagomir Negative Control is a chemically-modified oligonucleotide (2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification), and can be used as a negative control. The sequence of MicroRNA Antagomir Negative Control is derived from cel-mir-239b. It has minimal sequence identity with miRNAs in human, mouse, and rat.
3
3 Cited Publications
Forschungsgebiete:
DDO-2728 (compound 19) is a selective AlkB homologue 5 (ALKBH5) inhibitor with an IC50 of 2.97 μM. DDO-2728 increases the abundance of N 6 methyladenosine (m 6A) modifications, inducing cell apoptosis and cycle arrest. DDO-2728 suppresses tumor growth in the MV4 11 xenograft model with favorable safety profile, shows the potential of targeting ALKBH5 in cancer research .
3
3 Cited Publications
Art. -Nr.: HY-W037893
CAS. Nr.: 122323-88-0
Synonyms: Methyl piperazine-2-carboxylate dihydrochloride; METTL3 activator-1
Forschungsgebiete:
CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1) dihydrochloride is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 dihydrochloride exhibits neuroprotective and anxiolytic potential by enhancing m 6A methylation modification of RNA. CHMA1004 dihydrochloride promotes HIV replication in an infection context. CHMA1004 dihydrochloride can be used in studies related to anxiety disorders and HIV-1 infection .
2
2 Cited Publications
CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC50 of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
